Patrick Hwu: The exciting use of tumor-infiltrating lymphocyte therapy for sarcoma

Patrick Hwu shared on X:

“In honor of Sarcoma Awareness Month, John E Mullinax, section head of Surgical Oncology at Moffitt Cancer Center, stopped by to chat with me about the exciting use of tumor-infiltrating lymphocyte (TIL) therapy for sarcoma.”

John E Mullinax, Section Head of Surgical Oncology at the Sarcoma Department at Moffitt Cancer Centre, replied:

“Thank you for inviting me to discuss our lab focus and early phase cell therapy trials in the sarcoma department. We have to do more for our patients with limited treatment options and this work is only possible because Moffitt Cancer Centre is a place that fosters innovation.”

Source: Patrick Hwu/X and John E Mullinax/X

Dr. Patrick Hwu, MD, currently serves as the President and CEO of Moffitt Cancer Center. With a focus on understanding the dynamics between tumors and the immune system, Dr. Hwu’s research has been pivotal in advancing gene-modified T cell therapy.

He notably contributed seminal work on the development of the first chimeric antigen receptor aimed at combating cancer. His research portfolio extends to vaccines, adoptive T-cell therapies, and mechanisms of immune resistance.

Before joining, Dr. Hwu held numerous leadership roles at The University of Texas MD Anderson Cancer Center for over 17 years. Notably, he served as the inaugural Chairman of the Department of Melanoma Medical Oncology in 2003, as well as the Associate Director of the Center for Cancer Immunology Research.

Additionally, he chaired the Department of Sarcoma Medical Oncology, demonstrating his commitment to advancing cancer treatment and research.